Encysive Pharmaceuticals Inc - Amended Statement of Changes in Beneficial Ownership (4/A)
08 4월 2008 - 7:28AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
January 31, 2008
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
PFIZER INC
|
2. Issuer Name
and
Ticker or Trading Symbol
ENCYSIVE PHARMACEUTICALS INC
[
ENCY
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
__
X
__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
235 EAST 42ND STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/1/2008
|
(Street)
NEW YORK, NY 10017
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
4/3/2008
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
4/1/2008
|
|
P
|
|
166666
(1)
|
A
|
$2.35
|
61931961
(1)
|
I
|
FN
(2)
|
Common Stock
|
4/2/2008
|
|
P
|
|
914512
(1)
|
A
|
$2.35
|
62846473
(1)
|
I
|
FN
(2)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(
1)
|
This amendment is made solely to correct the original Form 4 filed on April 3, 2008 to (i) remove the 8,473,574 shares that
had been included in the amount of securities beneficially owned on April 1, 2008 and the 7,512,764 shares that had been
included in the amount of securities benefically owned on April 2, 2008 because such shares were subject to guaranteed
delivery procedures and (ii) correct the amount of securities acquired on each of April 1, 2008 and April 2, 2008.
|
(
2)
|
Shares are directly owned by Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer Inc.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
PFIZER INC
235 EAST 42ND STREET
NEW YORK, NY 10017
|
|
X
|
|
|
Signatures
|
/s/ David Reid, Assistant Secretary of Pfizer Inc.
|
|
4/7/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Encysive Pharmaceuticals (MM) (NASDAQ:ENCY)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
Encysive Pharmaceuticals (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Encysive Pharmaceuticals Inc News Articles